Ticker

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City.…

Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price Requirement Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026 PRINCETON, N.J., Sept. 3, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and…

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new…

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.